Literature DB >> 6093531

Treatment and prevention of oropharyngeal candidiasis.

R Quintiliani, N J Owens, R A Quercia, J J Klimek, C H Nightingale.   

Abstract

As more potent antibacterial drugs are used to combat infections and as more patients with impaired defenses against infection are treated, other organisms, like fungi, have become important pathogens. Fungi of all types may appear in this setting, but Candida species are the most common, usually beginning as an infection in the oropharynx. Although oropharyngeal candidiasis usually remains localized, it may spread elsewhere, leading to a fatal outcome. Controversy still exists regarding the best drug to prevent or treat oropharyngeal candidiasis, but clotrimazole given as a troche may be the best choice at the moment owing to its high clinical success rate, safety, cost effectiveness, and high patient acceptability. There remains a need for more randomized and controlled studies comparing the efficacy of nystatin, ketoconazole, and clotrimazole in high-risk patients in whom invasive candidiasis remains a frequent problem.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093531

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity.

Authors:  N Vermerie; C Malbrunot; M Azar; P Arnaud
Journal:  Pharm World Sci       Date:  1997-08

2.  Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants. Antimycotics Study Group.

Authors:  J E Hoppe; H Hahn
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

3.  Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.

Authors:  Joel B Epstein; Edmond L Truelove; Kimberly Hanson-Huggins; Lloyd A Mancl; Alice Chen; Oliver W Press; Stephen H Petersdorf; Thomas R Fritsche; Joshua D Epstein
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

4.  Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study.

Authors:  Karl Wurstbauer; Florian Merz; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

5.  Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis.

Authors:  M A Pfaller; J Rhine-Chalberg; S W Redding; J Smith; G Farinacci; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

6.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28

7.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

8.  Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

Authors:  Jose A Vazquez
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.